Article
A pilot study of extremely low-frequency magnetic fields in advanced non-small cell lung cancer: Effects on survival and palliation of general symptoms
- Authors:
- Chengtao Sun
- Huiming Yu
- Xingwen Wang
- Junqing Han
-
View Affiliations / Copyright
Affiliations:
Department of Tumor Research and Therapy Center, Provincial Hospital Affiliated to Shandong University, Shandong University, Shandong 250021, P.R. China
-
Pages:
1130-1134
|
Published online on:
August 17, 2012
https://doi.org/10.3892/ol.2012.867
- Expand metrics +
Metrics:
Total
Views: 0
(Spandidos Publications: | PMC Statistics:
)
Metrics:
Total PDF Downloads: 0
(Spandidos Publications: | PMC Statistics:
)
This article is mentioned in:
Abstract
The inhibitory effects of magnetic fields (MFs) on tumor cell proliferation in vitro and in vivo have been reported in previous studies. However, the effects of MFs in the treatment of cancer have not been described in clinical trials. We investigated the effects of 420 r/min, 0.4‑T extremely low‑frequency MFs (ELF-MFs) on the survival and palliation of general symptoms in 13 advanced non-small cell lung cancer (NSCLC) patients. Toxicity and side‑effects were assessed according to WHO criteria. The treatment area included the primary tumor site, metastatic sites and metastatic lymph nodes. Additionally, the patients were treated 2 h per day, 5 days per week for 6-10 weeks. The changes in general symptoms were analyzed during ELF-MF treatment and 2 weeks after the completion of therapy. Results of physical examination, routine analysis of blood, ECG and liver function, biochemical and kidney function tests were evaluated before and following treatment. All 13 patients were followed up by outpatient service or telephone interview. Our results demonstrated that decreased pleural effusion, remission of shortness of breath, relief of cancer pain, increased appetite, improved physical strength, regular bowel movement and better sleep quality was detected in 2 (15.4%), 5 (38.5%), 5 (38.5%), 6 (46.2%), 9 (69.2%), 1 (7.7%) and 2 (15.4%) patients, respectively. However, the palliation of symptoms in 2 (15.4%) patients was observed during therapy and disappeared at treatment termination. No severe toxicity or side-effects were detected in our trial. The median survival was 6.0 months (95% CI, 1.0-11.0). The 1- and 2-year survival rates were 31.7 and 15.9%, respectively. This study is the first to describe survival and palliation of general symptoms in advanced NSCLC patients treated with ELF-MFs. As an effective, well-tolerated and safe treatment choice, ELF-MFs may prolong survival and improve general symptoms of advanced NSCLC patients. However, this treatment strategy requires further research.
View References
|
1.
|
L HuangL DongY ChenH QiD XiaoEffects of
sinusoidal magnetic field observed on cell proliferation, ion
concentration, and osmolarity in two human cancer cell
linesElectromagn Biol
Med25113126200610.1080/1536837060071906716771300
|
|
2.
|
S TofaniD BaroneM BerardelliE BernoM
CintorinoL FogliaP OssolaF RonchettoE TosoM EandiStatic and ELF
magnetic fields enhance the in vivo anti-tumor efficacy of
cis-platin against lewis lung carcinoma, but not of
cyclophosphamide against B16 melanotic melanomaPharmacol
Res4883902003
|
|
3.
|
VV NovikovGV NovikovEE FesenkoEffect of
weak combined static and extremely low-frequency alternating
magnetic fields on tumor growth in mice inoculated with the Ehrlich
ascites
carcinomaBioelectromagnetics30343351200910.1002/bem.20487
|
|
4.
|
X ZhangH ZhangC ZhengC LiX ZhangW
XiongExtremely low frequency (ELF) pulsed-gradient magnetic fields
inhibit malignant tumour growth at different biological levelsCell
Biol Int26599603200210.1006/cbir.2002.088312127939
|
|
5.
|
F RonchettoD BaroneM CintorinoM
BerardelliS LissoloR OrlassinoP OssolaS TofaniExtremely low
frequency-modulated static magnetic fields to treat cancer: A pilot
study on patients with advanced neoplasm to assess safety and acute
toxicityBioelectromagnetics25563571200410.1002/bem.20029
|
|
6.
|
E ElsonI. The little explored efficacy of
magnetic fields in cancer treatment and postulation of the
mechanism of actionElectromagn Biol
Med28275282200910.3109/1536837090311427120001703
|
|
7.
|
MJ Ruiz-GómezM
Martínez-MorilloElectromagnetic fields and the induction of DNA
strand breaksElectromagn Biol Med28201214200919811402
|
|
8.
|
HJ LeeYM GimmHD ChoiN KimSH KimYS
LeeChronic exposure of Sprague-Dawley rats to 20 kHz triangular
magnetic fieldsInt J Radiat
Biol86384389201010.3109/0955300090356792020397843
|
|
9.
|
T WangY NieS ZhaoY HanY DuY HouInvolvement
of midkine expression in the inhibitory effects of low-frequency
magnetic fields on cancer
cellsBioelectromagnetics32443452201110.1002/bem.2065421360556
|
|
10.
|
R de SezeS TuffetJM MoreauB VeyretEffects
of 100 mT time varying magnetic fields on the growth of tumors in
miceBioelectromagnetics21107111200010653621
|
|
11.
|
S TofaniD BaroneM CintorinoMM de SantiA
FerraraR OrlassinoP OssolaF PeroglioK RolfoF RonchettoStatic and
ELF magnetic fields induce tumor growth inhibition and
apoptosisBioelectromagnetics22419428200110.1002/bem.6911536283
|
|
12.
|
T HisamitsuK NaritaT KasaharaA SetoY YuK
AsanoInduction of apoptosis in human leukemic cells by magnetic
fieldsJpn J Physiol47307310199710.2170/jjphysiol.47.3079271162
|
|
13.
|
Z HuX ChenY ZhaoT TianG JinY ShuY ChenL
XuK ZenC ZhangH ShenSerum microRNA signatures identified in a
genome-wide serum microRNA expression profiling predict survival of
non-small-cell lung cancerJ Clin
Oncol2817211726201010.1200/JCO.2009.24.934220194856
|
|
14.
|
G GaoH ChuL ZhaoT GuiQ XuJ ShiA
meta-analysis of paclitaxel-based chemotherapies administered once
every week compared with once every 3 weeks first-line treatment of
advanced non-small-cell lung cancerLung
Cancer76380386201210.1016/j.lungcan.2011.12.00122226626
|
|
15.
|
S NovelloT Le ChevalierChemotherapy for
non-small-cell lung cancer. Part 1: Early-stage diseaseOncology
(Williston Park)17357364200312661267
|
|
16.
|
L GuoSP BaiL ZhaoXH WangAstragalus
polysaccharide injection integrated with vinorelbine and cisplatin
for patients with advanced non-small cell lung cancer: effects on
quality of life and survivalMed OncolSep182011(E-pub ahead of
print)
|
|
17.
|
L AdamsenM QuistJ MidtgaardC AndersenT
MøllerL KnutsenA TveteråsM RorthThe effect of a multidimensional
exercise intervention on physical capacity, well-being and quality
of life in cancer patients undergoing chemotherapySupport Care
Cancer14116127200610.1007/s00520-005-0864-x
|
|
18.
|
No authors listed: Chemotherapy in
non-small cell lung cancer: a meta-analysis using updated data on
individual patients from 52 randomised clinical trials. Non-small
Cell Lung Cancer Collaborative
GroupBMJ311899909199510.1136/bmj.311.7010.899
|
|
19.
|
A ArdizzoniL BoniM TiseoFV FossellaJH
SchillerM PaesmansD RadosavljevicA PaccagnellaP ZatloukalP
MazzantiD BissetR RosellCISCA (CISplatin versus CArboplatin)
Meta-analysis Group: Cisplatin-versus carboplatin-based
chemotherapy in first-line treatment of advanced non-small-cell
lung cancer: an individual patient data meta-analysisJ Natl Cancer
Inst99847857200710.1093/jnci/djk196
|
|
20.
|
A ChiapporiG BeplerF BarlesiJC SoriaM
ReckA BearzF BarataG ScagliottiK ParkA WagleAM LiepaYD ZhaoN
ChouakiN IscoeJ von PawelPhase II, double-blinded, randomized study
of enzastaurin plus pemetrexed as second-line therapy in patients
with advanced non-small cell lung cancerJ Thorac
Oncol5369375201010.1097/JTO.0b013e3181cee24f20090562
|
|
21.
|
WX QiZ ShenY YaoMeta-analysis of
docetaxel-based doublet versus docetaxel alone as second-line
treatment for advanced non-small-cell lung cancerCancer Chemother
Pharmacol6999106201210.1007/s00280-011-1678-921607554
|
|
22.
|
WX QiLN TangAN HeZ ShenY YaoEffectiveness
and safety of pemetrexed-based doublet versus pemetrexed alone as
second-line treatment for advanced non-small-cell lung cancer: a
systematic review and meta-analysisJ Cancer Res Clin
Oncol138745751201210.1007/s00432-012-1155-922258853
|
